NHIQ — Nanthealth Share Price
Last trade - 00:00- $1.37m
- $319.76m
- $67.00m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.02 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -69.14% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 89.46 | 77.43 | 73.17 | 62.65 | 67 | 81.2 | n/a | -5.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NantHealth, Inc. provides enterprise solutions that help businesses transform complex data into actionable insights. The Company is engaged in offering ways to move, interpret, and visualize complex and sensitive information to its customers in the healthcare, life sciences, logistics, telecommunications, and other industries to automate, understand, and act on data while keeping it secure and scalable. The Company’s products include Eviti Connect and Eviti Advisor, NaviNet, NaviNet Open, NaviNet AllPayer, OpenNMS, and Quadris. Its product portfolio comprises the technology in payer/provider collaboration platforms for real-time coverage decision support (Eviti and NaviNet) and data solutions that include multi-data analysis, reporting, and professional service offerings (Quadris). In addition, The OpenNMS Group, Inc. (OpenNMS), the Company’s subsidiary, helps businesses monitor and manage network health and performance.
Directors
- Patrick Soon-Shiong CHM (68)
- Bob Petrou CFO (49)
- Ronald Louks COO (56)
- Michael Blaszyk IND (68)
- Kirk Calhoun IND (77)
- Michael Sitrick IND (73)
- Deanna Wise IND (52)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- July 7th, 2010
- Public Since
- June 2nd, 2016
- No. of Shareholders
- 111
- No. of Employees
- 364
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 27,471,346
- Address
- 3000 RDU CENTER DRIVE, SUITE 200, MORRISVILLE, 27560
- Web
- https://nanthealth.com/
- Phone
- +1 3108537513
- Auditors
- Ernst & Young LLP
Upcoming Events for NHIQ
Similar to NHIQ
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 22:11 UTC, shares in Nanthealth are trading at $0.05. This share price information is delayed by 15 minutes.
Shares in Nanthealth last closed at $0.05 and the price had moved by -85.34% over the past 365 days. In terms of relative price strength the Nanthealth share price has underperformed the S&P500 Index by -86.14% over the past year.
The overall consensus recommendation for Nanthealth is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNanthealth does not currently pay a dividend.
Nanthealth does not currently pay a dividend.
Nanthealth does not currently pay a dividend.
To buy shares in Nanthealth you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.05, shares in Nanthealth had a market capitalisation of $1.37m.
Here are the trading details for Nanthealth:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NHIQ
Based on an overall assessment of its quality, value and momentum Nanthealth is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Nanthealth is $4.00. That is 7900% above the last closing price of $0.05.
Analysts covering Nanthealth currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nanthealth. Over the past six months, its share price has outperformed the S&P500 Index by +2600.56%.
As of the last closing price of $0.05, shares in Nanthealth were trading -86.73% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nanthealth PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Nanthealth's management team is headed by:
- Patrick Soon-Shiong - CHM
- Bob Petrou - CFO
- Ronald Louks - COO
- Michael Blaszyk - IND
- Kirk Calhoun - IND
- Michael Sitrick - IND
- Deanna Wise - IND